4SC and Schering Sign Research Collaboration for The Identification of Novel Drug Candidates
MARTINSRIED, Germany, Oct. 8 - 4SC AG announced today the signing of a research collaboration with Schering AG to identify novel molecules, that bind to a specific undisclosed target provided by Schering, to serve as the basis for drug discovery. Under the terms of the agreement, 4SC will use its proprietary virtual High Throughput Screening technology, 4SCan(R), to evaluate a proprietary pool of 3.3 million small organic molecules for their binding efficacy to the given target. Schering will then receive a selection of ranked molecules for biological testing and further evaluation. In return 4SC will receive undisclosed research funding and milestone payments.
"This collaboration confirms that our time and cost-efficient cheminformatic approach for the development of new drug candidates appeals to a global pharmaceutical player such as Schering," stated Dr. Ulrich Dauer, CEO of 4SC. "We look forward to collaborating with Schering."
"We are very interested in new approaches and technologies that increase efficiency in the field of drug discovery, in particular if these technologies contribute to accelerating the early stages in the drug discovery process. We hope that cost and time savings will be achieved by using 4SCan(R)," commented Dr. Nikolaus Heinrich, Head of Computational Chemistry of Schering.
Most read news
Other news from the department science

Get the chemical industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.